Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

Hope S. Rugo, MD
Published Online: Monday, Jul 17, 2017



Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

There is a substantial risk of recurrence after 5 years for patients with endocrine-sensitive HR+ breast cancer, explains Rugo. From current trials, there is still ongoing recurrence in this patient population, however those rates are lower than what was previously thought, states Rugo.
 


Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

There is a substantial risk of recurrence after 5 years for patients with endocrine-sensitive HR+ breast cancer, explains Rugo. From current trials, there is still ongoing recurrence in this patient population, however those rates are lower than what was previously thought, states Rugo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x